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The American Diabetes Association(ADA) recently introduced new diag-nostic criteria for the diagnosis of dia-
betes (1). In contrast to the 1985 Wo r l d
Health Organization (WHO) criteria (2),
the ADA criteria are based on fasting
plasma glucose (FPG) levels only, and con-
sequently an oral glucose tolerance test
(OGTT) is no longer re q u i red. Furt h e r-
m o re, ADA set the FPG cutoff point for the
diagnosis of diabetes at 7.0 mmol/l (1).
Several studies have already shown
poor agreement between the ADA and the
WHO criteria. In the Decode Study, in
which data from eight European countries
w e re analyzed, the national changes in
p revalence of diabetes ranged from a re d u c-
tion of 4% to an increase of 13% when
applying the new ADA diagnostic criteria
(3). In the Hoorn Study, both sets of criteria
led to similar prevalence figures, but 40% of
the subjects newly diagnosed with diabetes
a c c o rding to the WHO criteria had no dia-
betes according to the ADA criteria (4).
With either set of criteria, a considerable
number of individuals with an adverse car-
diovascular risk profile will not be diag-
nosed (4). Other studies also showed a larg e
variation in individual classification (5–10).
At the time that the ADA criteria were
i n t roduced, no data were available re g a rd-
ing the mortality risks for the individuals
diagnosed with diabetes by the new criteria.
Although diagnostic criteria for diabetes a re
based on the presence of micro v a s c u l a r
complications, diabetic individuals also are
at risk for cardiovascular complications and
c a rdiovascular mortality (11,12). There-
f o re, prospective data are needed to assess
which set of criteria best identifies individ-
uals at high risk for mortality and card i o-
vascular disease (CVD).
In epidemiological studies, the diagno-
sis of diabetes is often based on one abnor-
mal diagnostic test. Both the ADA and the
WHO criteria emphasize that, for use in
clinical practice, the diagnosis of diabetes
should always be confirmed by re p e a t i n g
the test on another day (1,2).
In the present study, we compared the
risk of all-cause and CVD mortality in the
ADA and WHO glucose tolerance cate-
gories after 9 years of follow-up in the
H o o rn Study. Furt h e rm o re, we analyzed
the test–retest re p roducibility of the ADA
and the WHO criteria.
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Similar 9-Year Mort a l ity Risks and
R e p ro d u c i b i l ity for the World Health
O rganization and American Diabetes
Association Glucose Tolerance Categories
The Hoorn Study
O R I G I N A L  A R T I C L E
O B J E C T I V E — To compare the risks of all-cause and cardiovascular disease (CVD) mort a l i t y
in the American Diabetes Association (ADA) and World Health Organization (WHO) glucose
tolerance categories after 9 years of follow-up in the Hoorn Study and to study the test–re t e s t
re p roducibility of those categories.
RESEARCH DESIGN AND METHODS — In this population-based cohort study of
2,468 elderly men and women, subjects were classified according to both the WHO and the
ADA criteria. Causes of death were extracted from the medical re c o rds. Age- and sex-
adjusted relative risks were estimated by Cox’s pro p o rtional hazards model. Repro d u c i b i l i t y
of the diagnostic criteria was assessed in a sample of 1,109 subjects with duplicate oral glu-
cose tolerance tests.
R E S U LT S — Subjects with known diabetes had a four to five times higher risk of all-cause
and CVD mortality compared with normal subjects (P 0.05). The relative risks of all-cause
m o rtality were 1.67 (95% CI 1.09–2.57) and 1.56 (1.00–2.43) for newly diagnosed diabetic
subjects according to the WHO and ADA criteria, re s p e c t i v e l y. The WHO and ADA criteria had
similar levels of re p ro d u c i b i l i t y. The overall was 0.59 (0.54–0.64) for WHO criteria and 0.61
(0.56–0.66) for ADA criteria. For the category of newly diagnosed diabetes according to WHO
or ADA, the percentages of agreement for the second test compared with the first test were 77%
(85/110) and 74% (74/100), re s p e c t i v e l y.
C O N C L U S I O N S— Both sets of diagnostic criteria identify criteria-specific diabetic subjects
with an increased mortality risk compared with normal subjects, and the re p roducibility of both
criteria is similar. 
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RESEARCH DESIGN AND 
M E T H O D S
Cohort population
The Hoorn Study, which began in 1989, is
a population-based cohort study of glu-
cose intolerance in a general elderly popu-
lation. The study population has been
described in detail (13). In short, a random
sample of 3,553 men and women aged
50–75 years were invited to take part in the
H o o rn Study; 2,540 subjects (71%) agre e d .
A total of 56 non-Caucasians were
excluded from the study, which resulted in
the final Hoorn Study cohort of 2,484 men
and women. In the present study, 16 sub-
jects were excluded because of missing glu-
cose values, which resulted in a study
population of 2,468 subjects. All subjects
gave their written informed consent. The
Ethics Committee of the University Hospi-
tal Vrije Universiteit approved the study.
Follow-up
The vital status of participants was pro-
vided by the Population Register of the city
of Hoorn. Causes of death were extracted
f rom the medical re c o rds of the general
practitioners and the local hospital. The
I n t e rnational Classification of Diseases, Ninth
R e v i s i o n (ICD-9) (14) was used to code the
causes of death. CVD mortality was defined
as ICD-9 codes 390–459 (diseases of the
c i rc u l a t o ry system) or 798 (sudden death,
cause unknown) because sudden death in
general is of CVD origin (15). A cert i f i e d
nosologist at the local hospital in Hoorn
checked the ICD-9 codes assigned to the
causes of death by one of the authors
( F. d . V.) for a sample of 52 subjects; the
a g reement for the category of CVD mort a l-
ity was high (94%). The vital status for the
subjects who had moved out of Hoorn (n =
180) was checked in the population re g i s-
ters of the cities to which they had moved.
Glucose tolerance categories
At the baseline examinations (1989–
1990), a blood sample was taken from all
subjects after an overnight fast, after which
a 75-g OGTT was administered. A glucose
d e h y d rogenase method (Merck, Darm-
stadt, Germany) was used to determ i n e
FPG and 2-h postload glucose (2-h PG)
levels. All subjects were classified in glu-
cose tolerance categories according to the
WHO and the ADA criteria (1,2). Subjects
who were already re g i s t e red as diabetic
patients (i.e., subjects taking insulin or
oral hypoglycemic agents or subjects
t reated with diet) were classified as having
known diabetes.
In a subset of 1,109 subjects stratified
for glucose tolerance status at the baseline
examination, a second OGTT was per-
f o rmed after 2–6 weeks (16). These sub-
jects were classified according to both the
WHO and the ADA criteria (1,2) at both
the first visit and at the second visit to
d e t e rmine the re p roducibility of the ADA
and the WHO criteria.
Statistical methods
To study possible diff e rences in surv i v a l ,
Kaplan-Meier curves were made for the
glucose tolerance categories according to
both sets of criteria. Because age and sex are
possible confounders in the association
between glucose tolerance and mort a l i t y,
age- and sex-adjusted relative risks (RRs)
and 95% CIs were calculated by using
C o x ’s pro p o rtional hazards model for the
WHO and the ADA glucose tolerance cat-
egories separately. Subsequently, the same
analyses were perf o rmed for glucose toler-
ance categories in which the WHO and the
ADA criteria were combined (i.e., concor-
dant and discordant glucose tolerance
analyses were made).
In the subset of 1,109 subjects, the
re p roducibility of the WHO and the ADA
criteria was examined by making cro s s -
tables with the glucose tolerance categories
of the first and second visits. The overall 
(which measures the agreement across t h e
glucose tolerance categories at the first and
second visits) and 95% CIs were calculated.
A value 0.75 re p resents excellent agre e-
ment, values of 0.40 re p resent poor
a g reement, and values between 0.40 and
0.75 re p resent fair to good agreement (17).
All analyses were perf o rmed with the
SPSS for Windows 6.1 software pro g r a m
(18). All P values were based on two-sided
tests, and the cutoff for statistical signifi-
cance was 0.05.
Figure 1—Survival for the various glucose tolerance categories according to the WHO (A) and ADA
(B) criteria. KDM, known diabetes; NDM, newly diagnosed diabetes; NFG, normal fasting glucose;
NGT, normal glucose tolerance.
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R E S U LT S — The study population con-
sisted of 1,137 men and 1,331 women
with a mean age of 61.7 ± 7.3 years. Dur-
ing the 9 years of follow-up (until January
1999), 285 subjects died (11.6%). For 260
of those subjects (91.2%), the causes of
death were retrieved; 131 of them (50.4%)
had a CVD cause of death. Only 10 sub-
jects (0.4%) were lost to follow-up, mainly
because they had moved abro a d .
The Kaplan-Meier curves show surv i v a l
during the follow-up for glucose tolerance
categories according to the WHO (Fig. 1A)
and the ADA (Fig. 1B) criteria. The ten-
dency is similar for both criteria, although
the slopes for the ADA impaired fasting glu-
cose (IFG) and newly diagnosed diabetes
categories seem to be less distinct than the
WHO impaired glucose tolerance (IGT) and
newly diagnosed diabetes categories.
Table 1 shows age- and sex-adjusted
RRs for all-cause and CVD mort a l i t y. Sub-
jects with known diabetes (n = 90) had an
a p p roximately four times higher risk of all-
cause mortality (P 0.05). For subjects
diagnosed with newly diagnosed diabetes
a c c o rding to the WHO criteria, the age-
and sex-adjusted RR of all-cause mort a l i t y
was 1.67 (95% CI 1.09–2.57), and this
value was 1.56 (1.00–2.43) for newly diag-
nosed diabetic subjects according to the
ADA criteria. The RR for IFG was almost as
high (1.53 [1.11–2.11]). For CVD mort a l i t y,
the age- and sex-adjusted RRs also incre a s e d
for the categories of glucose intolerance,
but only the RRs for known diabetes were
statistically significant (P 0 . 0 5 ) .
When we combined both sets of crite-
ria (Table 2), subjects with known diabetes
had the highest age- and sex-adjusted risks
of all-cause (3.95 [2.72–5.73]) and CVD
(4.65 [2.77–7.80]) mort a l i t y. Discord a n t
newly diagnosed diabetic subjects diag-
nosed by only one set of criteria had much
lower RRs that were not statistically signifi-
cant compared with concordant newly
diagnosed diabetic subjects. However, the
d i s c o rdant newly diagnosed diabetes cate-
gories were very small and included only a
few cases.
WHO and ADA criteria had a similar
level of re p roducibility (Tables 3 and 4).
The overall values were 0.59 (0.54–0.64)
for the WHO criteria and 0.61 (0.56–0.66)
for the ADA criteria. The overall perc e n t-
ages of agreement were 81% ([706 1 1 2
85]/1109) for the WHO categories and
85% [(777 89 74)/1109] for the ADA
categories. For the category of newly diag-
nosed diabetes according to the WHO or
the ADA criteria, the agreement for the sec-
ond test compared with the first test was 77
(85/110) and 74% (74/100), re s p e c t i v e l y,
w h e reas for IGT (47%, 112/239) and IFG
(51%, 89/173), the agreement was lower.
C O N C L U S I O N S — After 9 years of
follow-up in the Hoorn Study, diabetic sub-
jects newly diagnosed by either the ADA or
the WHO criteria had an increased risk of
all-cause mortality compared with norm a l
subjects. The risk of CVD mortality was
also increased, although this was not statis-
tically significant.
The major reason to diagnose diabetes
at an early stage is to prevent complications.
T h e re f o re, diagnostic criteria must identify
subjects who are at high risk. The curre n t
WHO and ADA diagnostic criteria are based
mainly on the association of hyperg l y c e m i a
with microvascular complications (1,2).
H o w e v e r, early treatment of hyperg l y c e m i a
and associated CVD risk factors may also
a ffect the severely enhanced risk of CVD and
m o rt a l i t y.
In the present study, we did not find
clear diff e rences in mortality risks for sub-
jects classified with IGT, IFG, or newly
diagnosed diabetes according to either set
of criteria, despite poor agreement between
the ADA and the WHO criteria in the
H o o rn Study as described before (4).
Newly diagnosed diabetic subjects had an
i n c reased mortality risk of 1.56 with the
ADA criteria (borderline significant) and
1.67 with the WHO criteria (P 0 . 0 5 ) .
Table 1—Age- and sex-adjusted RRs of all-cause and CVD mortality for glucose tolerance
c a t e g o r i e s a c c o rding to both ADA and WHO criteria
C u t o ff values M o rt a l i t y
S u b j e c t s FPG/2-h PG (mmol/l) n % A l l - c a u s e C V D
WHO criteria
N o n d i a b e t i c 7.8/and 7 . 8 2 , 0 0 8 9 . 4 1 1
IGT 7.8/and 7.8–11.1 2 5 2 1 5 . 9 1.29 (0.91–1.82) 1.22 (0.73–2.05)
Newly diagnosed 7.8/or 1 1 / 1 1 1 8 2 0 . 3 1.67 (1.09–2.57) 1.52 (0.79–2.94)
d i a b e t e s
Known diabetes (by definition) 9 0 3 7 . 8 3.75 (2.60–5.42) 4.62 (2.77–7.71)
ADA criteria
N o n d i a b e t i c 6 . 1 1 , 9 7 3 9 . 3 1 1
IFG 6 . 1 – 7 . 0 2 8 5 1 6 . 5 1.53 (1.11–2.11) 1.24 (0.75–2.07)
Newly diagnosed 7 . 0 1 2 0 1 8 . 3 1.56 (1.00–2.43) 1.50 (0.78–2.89)
d i a b e t e s
Known diabetes (by definition) 9 0 3 7 . 8 3.83 (2.65–5.53) 4.62 (2.77–7.69)
Data are RRs (95% CIs).
Table 2—Age- and sex-adjusted RRs of all-cause and CVD mortality for glucose tolerance
categories concordant and discordant re g a rding ADA and WHO criteria
C u t o ff values
FPG/2-h PG M o rt a l i t y
C a t e g o ry ( m m o l / l ) n % A l l - c a u s e C V D
N o rmal (NFG/NGT) 6 . 1 / 7 . 8 1 , 7 9 1 8 . 8 1 1
IFG (ADA)/NGT (WHO) 6 . 1 – 7 . 0 / 7 . 8 1 9 5 1 5 . 5 1.56 (1.06–2.31) 1.09 (0.56–2.12)
IGT (WHO)/NFG (ADA) 6 . 1 / 7 . 8 – 1 1 . 1 1 6 3 1 4 . 7 1.25 (0.81–1.93) 1.05 (0.54–2.04)
IFG/IGT (ADA/WHO) 6 . 1 – 7 . 0 / 7 . 8 – 1 1 . 1 6 4 2 1 . 9 1.78 (1.03–3.09) 1.54 (0.67–3.54)
Newly diagnosed 7 . 0 – 7 . 8 / 1 1 . 1 4 7 6 . 4 0.60 (0.19–1.87) 1.21 (0.38–3.85)
diabetes (ADA only)
Newly diagnosed 7 . 0 / 1 1 . 1 4 5 1 1 . 1 1.02 (0.42–2.48) 1.27 (0.40–4.04)
diabetes (WHO only)
Newly diagnosed  7.0 or 1 1 . 1 7 3 2 6 . 0 2.19 (1.35–3.53) 1.68 (0.77–3. 66)
diabetes (ADA/WHO)
Known diabetes (by definition) 9 0 3 7 . 8 3.95 (2.72–5.73) 4.65 (2.77–7.80)
Data are RRs (95% CIs). NGT, normal glucose tolerance; NFG, normal fasting glucose.
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Until now, only two other large pro s p e c-
t i v e studies compared the associations
between mortality and diabetes according to
the ADA and WHO criteria. In the Decode
S t u d y, which involved a combined analysis
of 14 European cohort studies, no signifi-
cant diff e rence in mortality risk was evident
for concordant and discordant diabetic
men. In contrast, women with diabetes
a c c o rding to the 2-h PG levels had a mor-
tality ratio in between those with fasting dia-
betes and those with concordant diabetes
(19). In the Funagata Diabetes Study in
Japan, the hazard ratios for all-cause and
CVD mortality were higher for subjects
diagnosed with diabetes according to the
ADA criteria than for subjects diagnosed
a c c o rding to the WHO criteria. However,
subjects with IGT had a higher risk of CVD
m o rtality than subjects with IFG (20).
In the Hoorn Study (4), as in other
studies (8,10), subjects with diabetes
a c c o rding to the ADA or the WHO criteria
had an adverse CVD risk profile compare d
with subjects who had normal glucose val-
ues. The associated risks of mortality and
CVD may be reduced by early treatment of
CVD risk factors. If, in clinical practice, the
fasting ADA criteria are used for diagnosis
because of the convenience of re q u i r i n g
only a fasting blood sample, then individ-
uals with isolated postload diabetes will
not be diagnosed. Because the decision
re g a rding whether to treat CVD risk factors
is derived from risk stratification chart s ,
the diagnosis of diabetes may be the deci-
sive factor. Some risk stratification chart s
(21,22) present estimates of CHD risks
separately for normal and diabetic indi-
viduals. Because individuals with diabetes
have higher risk estimates, treatment of
CVD risk factors is indicated earlier. There-
f o re, assessing postload glucose values in
individuals at high risk for diabetes is
advised, e.g., when the individual has a
positive family history, is obese, or has an
ethnic origin with a high prevalence of
d i a b e t e s .
R e p roducibility is an important issue in
diagnosis. The present study is, as far as we
k n o w, the first study to compare dire c t l y
the test–retest re p roducibility of both the
ADA and the WHO criteria in a large study
population with duplicate OGTTs. Our
sample of 1,109 subjects was stratified for
glucose tolerance status at the first visit,
which resulted in a higher prevalence of
I G T, IFG, and diabetes compared with the
general population. We observed a similar
re p roducibility of the WHO and the ADA
criteria, as indicated by the values of 0.59
and 0.61, re s p e c t i v e l y, which re p resent fair
to good agreement (17). The known high
intra-individual variability of 2-h PG
(16,23,24) did not result in a diff e re n t
re p roducibility for the categorization based
on the ADA and the WHO criteria.
The percentage of agreement for the
diagnosis of diabetes was 77% when using
the WHO criteria and 74% when using the
ADA criteria. Yudkin et al. (25) showed a
lower agreement of 64% for diabetes
a c c o rding to the WHO criteria in a popu-
lation of 223 subjects also stratified for glu-
cose tolerance status. Ko et al. (8) observ e d
an agreement of 69% for subjects diag-
nosed with diabetes according to the ADA
criteria. In the present study, the perc e n t a g e
of agreement for IGT and IFG was poor, as
was observed in the studies mentioned
above (8,25). This probably is due to the
n a rrow ranges of FPG and 2-h PG defining
these categories (25).
In conclusion, both sets of diagnostic
criteria identify criteria-specific diabetic indi-
viduals with an increased mortality risk
c o m p a red with nondiabetic individuals, and
the re p roducibility of both criteria is similar.
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